Wave Life Sciences Ltd.
WVE
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company aā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$15.05
Price+1.45%
$0.22
1Y
Price
Market Cap
$2.468b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-678.5%
EBITDA Margin-707.8%
Net Profit Margin-590.3%
Free Cash Flow Margin-678.5%
EBITDA Margin-707.8%
Net Profit Margin-590.3%
Free Cash Flow MarginRevenue
$109.230m
+0.9%
1y CAGR+1000.5%
3y CAGR+727.6%
5y CAGREarnings
-$121.946m
-25.7%
1y CAGR-10.0%
3y CAGR-15.6%
5y CAGREPS
-$0.75
-7.1%
1y CAGR+12.3%
3y CAGR+12.5%
5y CAGRBook Value
$124.549m
$241.378m
Assets$116.829m
Liabilities$19.772m
DebtDebt to Assets
8.2%
-0.2x
Debt to EBITDAFree Cash Flow
-$198.170m
-30.4%
1y CAGR-195.3%
3y CAGR-157.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company